Literature DB >> 28275182

Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Keisuke Ojiro1,2,3, Xiaowang Qu1,2, Hyosun Cho1,2, Jang-June Park1,2, Annelise Vuidepot4, Nikolai Lissin4, Peter E Molloy4, Alan Bennett5, Bent K Jakobsen4, David E Kaplan1,2, James L Riley2, Kyong-Mi Chang6,2.   

Abstract

The antiviral effects of hepatitis C virus (HCV)-specific CD8 T cells have been shown in an HCV replicon system but not in an authentic infectious HCV cell culture (HCVcc) system. Here, we developed tools to examine the antigenicity of HCV-infected HLA-A2-positive Huh7.5 hepatoma cells (Huh7.5A2 cells) in activating HCV-specific CD8 T cells and the downstream antiviral effects. Infectious HCV epitope mutants encoding the well-defined genotype 1a-derived HLA-A2-restricted HCV NS3-1073 or NS5-2594 epitope were generated from a genotype 2a-derived HCV clone (Jc1Gluc2A) by site-directed mutagenesis. CD8 T-cell lines specific for NS3-1073 and NS5-2594 were expanded from HCV-seropositive persons by peptide stimulation in vitro or engineered from HCV-seronegative donor T cells by transduction of a lentiviral vector expressing HCV-specific T-cell receptors. HCV-specific CD8 T cells were cocultured with Huh7.5 cells that were pulsed with titrating doses of HCV epitope peptides or infected with HCV epitope mutants. HCV-specific CD8 T-cell activation (CD107a, gamma interferon, macrophage inflammatory protein 1β, tumor necrosis factor alpha) was dependent on the peptide concentrations and the relative percentages of HCV-infected Huh7.5A2 cells. HCV-infected Huh7.5A2 cells activated HCV-specific CD8 T cells at levels comparable to those achieved with 0.1 to 2 μM pulsed peptides, providing a novel estimate of the level at which endogenously processed HCV epitopes are presented on HCV-infected cells. While HCV-specific CD8 T-cell activation with cytolytic and antiviral effects was blunted by PD-L1 expression on HCV-infected Huh7.5A2 cells, resulting in the improved viability of Huh7.5A2 cells, PD-1 blockade reversed this effect, producing enhanced cytolytic elimination of HCV-infected Huh7.5A2 cells. Our findings, obtained using an infectious HCVcc system, show that the HCV-specific CD8 T-cell function is modulated by antigen expression levels, the percentage of HCV-infected cells, and the PD-1/PD-L1 pathways and has antiviral and cytotoxic effects.IMPORTANCE We developed several novel molecular and immunological tools to study the interactions among HCV, HCV-infected hepatocytes, and HCV-specific CD8 T cells. Using these tools, we show the level at which HCV-infected hepatoma cells present endogenously processed HCV epitopes to HCV-specific CD8 T cells with antiviral and cytotoxic effects. We also show the marked protective effect of PD-L1 expression on HCV-infected hepatoma cells against HCV-specific CD8 T cells.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD8 T cells; HCV-specific TCR; Huh7.5 cells; PD-1 blockade; coculture; lentiviral transduction

Mesh:

Substances:

Year:  2017        PMID: 28275182      PMCID: PMC5411593          DOI: 10.1128/JVI.02129-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  New hepatitis C therapies: the toolbox, strategies, and challenges.

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2014-03-12       Impact factor: 22.682

2.  TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Authors:  Anna Pasetto; Lars Frelin; Soo Aleman; Fredrik Holmström; Anette Brass; Gustaf Ahlén; Erwin D Brenndörfer; Volker Lohmann; Ralf Bartenschlager; Matti Sällberg; Antonio Bertoletti; Margaret Chen
Journal:  J Immunol       Date:  2012-09-28       Impact factor: 5.422

3.  Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody.

Authors:  Konduru S R Sastry; Chien Tei Too; Kaval Kaur; Adam J Gehring; Lionel Low; Alia Javiad; Teresa Pollicino; Li Li; Patrick T F Kennedy; Uri Lopatin; Paul A Macary; Antonio Bertoletti
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

4.  Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection.

Authors:  Hirotoshi Ebinuma; Nobuhiro Nakamoto; Yun Li; David A Price; Emma Gostick; Bruce L Levine; J Tobias; William W Kwok; Kyong-Mi Chang
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

5.  Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).

Authors:  Michael J Fuller; Benoit Callendret; Baogong Zhu; Gordon J Freeman; Dana L Hasselschwert; William Satterfield; Arlene H Sharpe; Lynn B Dustin; Charles M Rice; Arash Grakoui; Rafi Ahmed; Christopher M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

6.  Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells.

Authors:  MinKyung Yi; Rodrigo A Villanueva; David L Thomas; Takaji Wakita; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

Review 7.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

Authors:  Barbara Rehermann
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

8.  Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C.

Authors:  David E Kaplan; Kazushi Sugimoto; Kimberly Newton; Mary E Valiga; Fusao Ikeda; Ayse Aytaman; Frederick A Nunes; Michael R Lucey; Barbara A Vance; Robert H Vonderheide; K Rajender Reddy; Jane A McKeating; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness.

Authors:  Luke Uebelhoer; Jin-Hwan Han; Benoit Callendret; Guaniri Mateu; Naglaa H Shoukry; Holly L Hanson; Charles M Rice; Christopher M Walker; Arash Grakoui
Journal:  PLoS Pathog       Date:  2008-09-05       Impact factor: 6.823

View more
  4 in total

1.  Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients.

Authors:  Radwa R El-Tahan; Ahmed M Ghoneim; Hosam Zaghloul
Journal:  Virus Genes       Date:  2020-06-22       Impact factor: 2.332

Review 2.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 3.  Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches.

Authors:  Paola Fisicaro; Valeria Barili; Marzia Rossi; Ilaria Montali; Andrea Vecchi; Greta Acerbi; Diletta Laccabue; Alessandra Zecca; Amalia Penna; Gabriele Missale; Carlo Ferrari; Carolina Boni
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

Review 4.  Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors.

Authors:  Yoshie Kametani; Yusuke Ohno; Shino Ohshima; Banri Tsuda; Atsushi Yasuda; Toshiro Seki; Ryoji Ito; Yutaka Tokuda
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.